Sanofi has spent five years using Owkin's artificial intelligence to help it read biology. Now it wants Owkin's software to start making calls on its own.
The French pharmaceutical giant and the Franco-American AI biotech announced a multi-year collaboration on June 5 to co-develop what they call next-generation biopharma agents — autonomous AI systems that will be embedded directly into Sanofi's research and development workflows. The deal is backed by a five-year license for K Pro, Owkin's self-described AI Scientist, and it marks a meaningful escalation from the two companies' earlier work, which was largely about applying models to discrete scientific questions rather than handing software the run of the pipeline.
Under the agreement, Owkin will lead end-to-end development of AI agents purpose-built for Sanofi. The companies describe them as intelligent assistants capable of autonomously performing complex tasks across drug research and development, deployed through K Pro and designed to complement Sanofi's existing internal agentic AI capabilities. Neither company disclosed the financial terms of the new arrangement.
From Target ID to Autonomous Agents
The relationship dates to 2021. Owkin's own press materials describe a 90 million euro strategic partnership with Sanofi focused on target identification in oncology and patient subgrouping; MobiHealthNews, reporting on the same relationship, characterises the 2021 announcement as a 180 million dollar equity investment tied to an oncology collaboration spanning four cancer types. The two figures likely describe different components — an equity stake versus a research commitment — but the companies have not reconciled them publicly, and the discrepancy is worth noting for anyone trying to size the total capital at stake.
That original collaboration leaned heavily on federated learning, Owkin's signature technique for training models across hospital datasets without moving patient data. It later expanded into immunology, where Owkin's tools were used for drug positioning — matching assets in Sanofi's pipeline to indications and patient subgroups.
The new deal is a different proposition. K Pro, which Owkin launched in 2025 as an agentic co-pilot for biomedical R&D, combines multimodal patient data with specialised biological AI systems to support decisions from early discovery through clinical development, including competitive intelligence. The framing has shifted from “help our scientists analyse this” to “run this workflow.”
“Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI,” said Thomas Clozel, CEO and co-founder of Owkin. “Owkin believes that, with K Pro, Sanofi can further harness agentic systems within their own workflows, unlocking the full value of their data to accelerate better decisions across drug development.”
Sanofi's framing is more cautious, and more revealing about who is meant to remain in charge. “Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle,” said Emmanuel Frenehard, Sanofi's Chief Digital Officer. “By implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence as we continue to work to deliver transformative outcomes for patients.”
Analysis: Owkin Is Becoming a Licensor, Not a Partner
The Sanofi deal is the second of its kind in under a month. On May 13, Owkin announced a three-year K Pro licensing agreement with AstraZeneca, also built around bespoke biopharma agents, initially aimed at competitive-intelligence questions and integrated into AstraZeneca's IT infrastructure. Two of the world's largest pharmaceutical companies have now licensed the same platform inside four weeks.
That pattern says something about Owkin's business model as much as about agentic AI. The company spent a decade as a research collaborator, monetising discoveries and co-development milestones. K Pro turns it into something closer to enterprise software — recurring licence revenue, multi-year terms, deployment inside customer infrastructure. It is a less romantic business than discovering drugs, but a far more legible one to investors, particularly for a company that has also been busy restructuring: Owkin spun out its diagnostics arm as Waiv with 33 million dollars in financing in March, having previously incubated foundation-model company Bioptimus.
It also fits the broader shift the sector is talking about — AI biotech moving from foundational models to a clinical era, where the question is no longer whether a model can predict protein structure or stratify patients but whether those capabilities can be operationalised at industrial scale inside an organisation with regulatory obligations. Owkin's pitch, that it is building toward Biological Artificial Superintelligence capable of ultimately automating some of the hardest problems in R&D, is doing a lot of rhetorical work. The contracts underneath it are more modest and more interesting: workflow integration, decision support, governance-compliant deployment.
The market reaction was muted. Sanofi shares traded around 77.95 euros in the days after the announcement, up roughly 6.6 percent over the prior month but still down more than 5 percent year to date — the kind of move that suggests investors have not yet priced an AI R&D thesis into the stock.
What to Watch
Three things will determine whether this is infrastructure or theatre. First, disclosure: whether Sanofi management ever attributes specific R&D timeline, productivity or cost movements to agentic systems. Second, scope creep — whether the agents graduate from competitive intelligence and literature synthesis into decisions that touch trial design or candidate selection. Third, regulators. The FDA's drug evaluation centre has flagged a sharp rise in applications containing AI components and issued draft guidance in 2025 on AI supporting regulatory decision-making. An autonomous agent that shapes a submission is a governance problem no licence agreement has solved yet.
“Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI.”— Thomas Clozel, CEO and Co-founder, Owkin